Pan Yunhu, Chen Yitan, Ma Debin, Ji Zhiyu, Cao Fangyu, Chen Zhibin, Ning Yunye, Bai Chong
a Department of Respiratory and Critical Care Medicine, Changhai Hospital , Second Military Medical University , Yangpu District , Shanghai , China.
b Department of Respiratory Medicine , No. 92 Hospital of Chinese People's Liberation Army , Yanping District, Nanping , Fujian , China.
Exp Lung Res. 2016 Aug;42(6):286-95. doi: 10.1080/01902148.2016.1207726. Epub 2016 Jul 27.
As one of the leading cause of cancer-related deaths in the worldwide, lung cancer needs to be understood better. Nowadays, increasing point mutations of specific oncogenes are biomarkers used to predict the therapeutic effect of targeted therapy and lung cancer has entered the age of individual treatment. At present, many relevant researchers have suggested that EGFR is a biomarker used to predict the therapeutic effect of targeted therapy. A large number of evidence indicates that EGFR/Akt pathway plays important role in cancer growth and metastasis.
In this paper, we found EGFR was a target of miR-646.
Overexpression of miR-646 not only downregulated EGFR/Akt pathway, but also inhibited lung cancer cell proliferation and metastasis. At the same time, miR-646 was a prognosis factor for overall survival.
Our finding could provide new insights into the molecular therapeutic of lung cancer.
作为全球癌症相关死亡的主要原因之一，肺癌需要被更好地了解。如今，特定癌基因中不断增加的点突变作为生物标志物用于预测靶向治疗的疗效，肺癌已进入个体化治疗时代。目前，许多相关研究人员表明表皮生长因子受体（EGFR）是一种用于预测靶向治疗疗效的生物标志物。大量证据表明，EGFR/Akt信号通路在癌症生长和转移中起重要作用。
在本文中，我们发现EGFR是miR-646的一个靶点。
miR-646的过表达不仅下调了EGFR/Akt信号通路，还抑制了肺癌细胞的增殖和转移。同时，miR-646是总生存期的一个预后因素。
我们的发现可为肺癌的分子治疗提供新的见解。
